Document is current
Any future updates will be listed below
-
Authors
Daniell, Henry
Wakade, Geetanjali
Singh, Rahul
Nair, Smruti
Basak, Saroj K.
Srivatsan, Eri S.
Bur, Andrés M.
Thomas, Sufi M.
Wang, Marilene B.
-
Funding
Funding for this research was provided by:
National Institutes of Health, USA (5-R01-HL 107904-13)
- License Information
-
More Information
Article History
Received: 19 February 2025
Accepted: 2 February 2026
First Online: 9 February 2026
Declarations
:
: HD is a patentee in plant-based oral and topical drug delivery and was previously funded by Novo Nordisk, Bayer, Shire and Takeda. List of awarded and published patents are available in Google Scholar and Scholar GPS links below. However, there is no specific financial conflict related to this manuscript. All other authors declare that they have no competing interests. Scholar GPS: Scholar: .
: Salivary samples from non-cancer and oral cancer patients were collected after obtaining approval from the IRB committee of the Veterans Administration of Greater Los Angeles Healthcare System (VAGLAHS), Los Angeles, California (IRB study #1615727). Informed consent approval was obtained from all cancer and non-cancer volunteers. The IRB at the University of Kansas School of Medicine approved the study (IRB# STUDY00001732). Informed consent was obtained from patients prior to commencement of all study activities. Samples collected from HNSCC patients and cancer-free participants were deidentified after obtaining written consent.
